Application of a newly developed ELISA for BCAR1 protein for prediction of clinical benefit of tamoxifen therapy in patients with advanced breast cancer

Clinical Chemistry

Volumn 50, Issue 8, 2004, Pages 1445-1447

  Dorssers, Lambert C J ^a   Grebenchtchikou, Nicolai ^b   Brinkman, Arena ^a   Look, Maxime P ^a   Klijn, Jan G M ^a   Geurts Moespot, Anneke ^b   Span, Paul N ^b   Foekens, John A ^a   Sweep, C G J ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; BREAST CANCER ANTI ESTROGEN RESISTANCE PROTEIN 1; BREAST CANCER RESISTANCE PROTEIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MENOPAUSE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PROGNOSIS; PROTEIN ANALYSIS; RANK SUM TEST; RECURRENT CANCER; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CRK-ASSOCIATED SUBSTRATE PROTEIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROTEINS; RETINOBLASTOMA-LIKE PROTEIN P130; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 3242781739     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2004.035493     Document Type: Article

References (15)

1. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001;53:25-71.
2. Brinkman A, Van der Flier S, Kok EM, Dorssers LCJ. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 2000;92:112-20.
3. Foekens JA, Portengen H, Van Putten WLJ, Peters HA, Krijnen HLJM, Alexieva-Figusch J, et al. Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 1989;49:5823-8.
4. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A, Rubens RD. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 1977;39:1289-93.
5. EORTC Breast Cancer Cooperative Group. Manual for clinical research and treatment in breast cancer. Almere, The Netherlands: Excerpta Medical, 2000:116-7.
6. Foekens JA, Portengen H, Look MP, Van Putten WLJ, Thirion B, Bontenbal M, et al. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer. Br J Cancer 1994;70:1217-23.
7. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992;10:1284-91.
8. Robertson JF, Willsher PC, Cheung KL, Blamey RW. The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer. Eur J Cancer 1997;33:1774-9.
9. Grebenchtchikov N, Brinkman A, van Broekhoven SPJ, de Jong D, Geurts-Moespot A, Span PN, et al. Development of an ELISA for measurement of BCAR1 protein in human breast cancer tissue. Clin Chem 2004;50:1356-63.
10. EORTC Breast Cancer Cooperative Group. Revision of the standards for the assessment of hormone receptors in human breast cancer; report of the second E.O.R.T.C. Workshop, held on 16-17 March, 1979, in the Netherlands Cancer Institute. Eur J Cancer 1980;16:1513-5.
11. Barlow RE, Bartholomew DJ, Bremner JM, Brunk HD. Statistical inference under order restrictions. New York: John Wiley & Sons, 1972:388pp.
12. Bouton AH, Riggins RB, Bruoe-Staskal PJ. Functions of the adapter protein Cas: signal convergence and the determination of cellular responses. Oncogene 2001;20:6448-58.
13. O'Neill GM, Fashena SJ, Golemis EA. Integrin signalling: a new Cas(t) of characters enters the stage. Trends Cell Biol 2000;10:111-9.
14. Van der Flier S, Brinkman A, Look MP, Kok EM, Meijer-Van Gelder ME, Klijn JGM, et al. Bcar1/p130Cas protein and primary breast cancer: prognosis and response to tamoxifen treatment. J Natl Cancer Inst 2000;92:120-7.
15. Zhang XA, He B, Zhou B, Liu L. Requirement of the p130CAS-Crk coupling for metastasis suppressor KAI1/CD82-mediated inhibition of cell migration. J Biol Chem 2003;278:27319-28.